Shenzhen New Industries Biomedical Working Capital to Net Assets Ratio
Shenzhen New Industries Biomedical working capital to net assets ratio. Shenzhen New Industries Biomedical (300832) has a Working Capital to Net Assets ratio of 51.7% as of September 2025. Working capital of CN¥4.52 Billion (current assets of CN¥5.20 Billion minus current liabilities of CN¥680.50 Million) is measured against net assets of CN¥8.74 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Shenzhen New Industries Biomedical's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shenzhen New Industries Biomedical (2012–2024)
Working capital to net assets ratio of Shenzhen New Industries Biomedical from 2012 to 2024. This chart shows how Shenzhen New Industries Biomedical's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at 51.7%, reflecting working capital of CN¥4.52 Billion against net assets of CN¥8.74 Billion CNY. See 300832 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Shenzhen New Industries Biomedical Working Capital to Net Assets Ratio by Year (2012–2024)
Shenzhen New Industries Biomedical working capital to net assets ratio by year from 2012 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Shenzhen New Industries Biomedical from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Shenzhen New Industries Biomedical.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 48.4% | CN¥4.15 Billion | CN¥8.58 Billion | CN¥5.06 Billion | CN¥908.74 Million | ▼ -10.9 pp |
| 2023 | 59.3% | CN¥4.47 Billion | CN¥7.54 Billion | CN¥5.06 Billion | CN¥591.48 Million | ▼ -6.9 pp |
| 2022 | 66.2% | CN¥4.24 Billion | CN¥6.40 Billion | CN¥4.82 Billion | CN¥583.94 Million | ▼ -4.9 pp |
| 2021 | 71.1% | CN¥3.99 Billion | CN¥5.61 Billion | CN¥4.50 Billion | CN¥507.94 Million | ▼ -4.5 pp |
| 2020 | 75.6% | CN¥3.63 Billion | CN¥4.80 Billion | CN¥4.12 Billion | CN¥492.74 Million | ▲ +6.3 pp |
| 2019 | 69.3% | CN¥2.18 Billion | CN¥3.14 Billion | CN¥2.48 Billion | CN¥308.37 Million | ▲ +1.6 pp |
| 2018 | 67.7% | CN¥1.60 Billion | CN¥2.37 Billion | CN¥1.87 Billion | CN¥264.18 Million | ▲ +0.2 pp |
| 2017 | 67.5% | CN¥1.20 Billion | CN¥1.77 Billion | CN¥1.44 Billion | CN¥239.16 Million | ▼ -6.3 pp |
| 2016 | 73.7% | CN¥1.05 Billion | CN¥1.42 Billion | CN¥1.21 Billion | CN¥159.11 Million | ▲ +8.8 pp |
| 2015 | 64.9% | CN¥664.44 Million | CN¥1.02 Billion | CN¥771.83 Million | CN¥107.39 Million | ▲ +9.6 pp |
| 2014 | 55.3% | CN¥337.63 Million | CN¥610.52 Million | CN¥449.30 Million | CN¥111.67 Million | ▼ -17.3 pp |
| 2013 | 72.6% | CN¥274.91 Million | CN¥378.84 Million | CN¥358.46 Million | CN¥83.55 Million | ▼ -25.6 pp |
| 2012 | 98.2% | CN¥243.67 Million | CN¥248.18 Million | CN¥289.66 Million | CN¥45.99 Million | — |